Many BCR-ABL1 compound mutations reported in chronic myeloid leukemia patients may actually be artifacts due to PCR-mediated recombination-Reference-Cited by-同舟云学术

Many BCR-ABL1 compound mutations reported in chronic myeloid leukemia patients may actually be artifacts due to PCR-mediated recombination

Published:2014-07-03 Issue:1 Volume:124 Page:153-155
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Parker Wendy T.¹,Phillis Stuart R.²,Yeung David T. O.³⁴,Hughes Timothy P.⁵⁴⁶,Scott Hamish S.²⁷⁸,Branford Susan²⁷⁸

Affiliation:

1. Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia School of Pharmacy and Medical Science, University of South Australia, Adelaide, Australia

2. Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia

3. Departments of Genetics and Molecular Pathology and Hematology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia

4. School of Medicine, University of Adelaide, Adelaide, Australia

5. Department of Hematology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia

6. Cancer Theme, South Australian Health and Medical Research Institute, Adelaide, Australia

7. Schools of Medicine and Molecular and Biomedical Science, University of Adelaide, Adelaide, Australia

8. School of Pharmacy and Medical Science, University of South Australia, Adelaide, Australia

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/124/1/153/1379054/153.pdf

Reference10 articles.

1. Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy.;Gibbons;Proc Natl Acad Sci U S A,2014

2. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.;O’Hare;Cancer Cell,2009

3. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors.;Zhang;Nature,2010

4. BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships.;Khorashad;Blood,2013

5. Rapid identification of compound mutations in patients with Philadelphia-positive leukaemias by long-range next generation sequencing.;Kastner;Eur J Cancer,2014

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Novel Next-Generation Sequencing Assay for the Identification of BCR::ABL1 Transcript Type and Accurate and Sensitive Detection of TKI-Resistant Mutations;The Journal of Applied Laboratory Medicine;2024-09-03

2. Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies;MedComm;2024-08-24

3. Resistance mutations in CML and how we approach them;Hematology;2023-12-08

4. Disease Response Assessment Modalities in Chronic Myeloid Leukemia: Past, Present, and Future;Indian Journal of Medical and Paediatric Oncology;2023-11-27

5. European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia;Leukemia;2023-10-04